Delivery Order SPE2DB20D3303-SPE2DB25FA2LE
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of Ondansetron ODT 4 mg tablets (30-count units) with a ceiling value of $3,686.07. This competitively awarded, firm fixed-price delivery order represents a continuation of the contractor's critical role in supporting federal pharmaceutical procurement. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters...
- The Defense Logistics Agency awarded a delivery order valued at $8,736.12 to AmerisourceBergen Drug Corp for the supply of Ondansetron ODT 4 MG tablets in quantities of 30 units. This competitive award, issued on July 21, 2025, with an ultimate completion date of July 22, 2025, represents a firm fixed-price delivery order with no set-aside designation. The product will be delivered to Conshohocken, Pennsylvania, the location of AmerisourceBergen's corporate headquarters. This delivery order...
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on July 29, 2025, for the supply of Ondansetron ODT 4 mg tablets in a quantity of 30 units, with a ceiling value of $13,637.20. This is a firm fixed-price, non-set-aside delivery order with an ultimate completion date of July 30, 2025, and represents a child contract under AmerisourceBergen's larger federal contract portfolio. AmerisourceBergen Drug Corp, headquartered in...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 23, 2025, for the supply of Ondansetron ODT 4 mg tablets (30-count units) with a ceiling value of $8,001.71. This is a firm fixed price, non-competitive delivery order executed under the company's broader Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion global pharmaceutical support vehicle running through December 2026. The order will be performed at...
- The Defense Logistics Agency awarded a delivery order valued at $1,962.99 to AmerisourceBergen Drug Corp for the supply of Ondansetron ODT 4 mg tablets (30-count packaging) on July 23, 2025, with an ultimate completion date of July 24, 2025. This competitively awarded, firm fixed-price delivery order represents a small-value pharmaceutical procurement with no set-aside designation. The place of performance is listed as Conshohocken, Pennsylvania, which is also the location of AmerisourceBergen...
- The Defense Logistics Agency awarded a delivery order valued at $35,913.34 to AmerisourceBergen Drug Corp for the supply of Ondansetron ODT 8 mg tablets (30-count) on August 4, 2025, with an ultimate completion date of August 5, 2025. This competitively awarded, firm fixed-price delivery order was issued with no set-aside designation and specifies Conshohocken, Pennsylvania as the place of performance, which aligns with the contractor's corporate headquarters location. The award represents a...
- The Defense Logistics Agency awarded a $5,629.86 delivery order to AmerisourceBergen Drug Corp for Ondansetron ODT 4 mg tablets (30-count supply) on July 24, 2025, with an ultimate completion date of July 25, 2025. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded through open competition. The place of performance is located in Conshohocken, Pennsylvania, which is also the headquarters location of the prime contractor. This delivery order is issued...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $7,882.56 to AmerisourceBergen Drug Corp for the supply of Ondansetron ODT 4 mg tablets (30-count units). This is a firm fixed price delivery order with no set-aside designation, competitively awarded and completed on August 8, 2025. The contract was performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a delivery order valued at $3,938.52 to AmerisourceBergen Drug Corp for the supply of Ondansetron ODT 4 mg tablets (30-count units). This competitively awarded, firm fixed-price contract is scheduled for completion by August 4, 2025, with performance at the contractor's corporate headquarters in Conshohocken, Pennsylvania. The award carries no set-aside designation and represents a continuation of AmerisourceBergen's extensive pharmaceutical supply...
- The Defense Logistics Agency awarded a delivery order valued at $5,660.39 to AmerisourceBergen Drug Corp for the supply of Ondansetron ODT 4 MG tablets (30-count packages) with a firm fixed price structure. The contract, awarded July 31, 2025, represents a non-set-aside, competitively awarded delivery order with an ultimate completion date of August 1, 2025. Performance will be executed from the vendor's location in Conshohocken, Pennsylvania, the company's corporate headquarters. This...
- SPE2DB20D3303Indefinite Delivery Contract
- SPE2DB20D3303-SPE2DB25FA2LEDelivery Order
The Defense Logistics Agency awarded a $5,730.89 firm fixed-price delivery order to AmerisourceBergen Drug Corp for 30-count bottles of Ondansetron ODT 4 mg tablets, with completion targeted for August 13, 2025. This non-set-aside contract was competitively awarded and represents a single delivery order under AmerisourceBergen's larger pharmaceutical supply arrangement with DLA. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania, where the company serves as a major pharmaceutical distributor specializing in federal medical procurement for military and veteran healthcare systems. This delivery order falls under AmerisourceBergen's broader Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 through December 2026. This comprehensive contract vehicle enables the company to supply a wide range of pharmaceutical products and medical supplies to support military healthcare programs globally, including medications, vaccines, and specialized medical commodities. Ondansetron, an antiemetic commonly used in medical settings to prevent nausea and vomiting, represents the type of essential pharmaceutical that supports the Defense Health Agency and other government healthcare systems through this flexible contracting mechanism.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $5.7k | 8/12/25 |